US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

30.84

-0.0900-0.29%

Post-market: 30.840.00000.00%17:01 EST

Volume:355.18K

Turnover:10.95M

Market Cap:1.49B

PE:-18.18

High:31.80

Open:31.20

Low:30.22

Close:30.93

52wk High:31.80

52wk Low:5.49

Shares:48.41M

Float Shares:22.41M

Volume Ratio:0.98

T/O Rate:1.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6961

EPS(LYR):-3.8737

ROE:--

ROA:--

PB:3.09

PE(LYR):-7.96

Loading ...

Overview Company News Filings

Kaishan Group's Subsidiary KS ORKA Signs Joint Venture LOI with Hungarian Partner to Advance Geothermal Power Projects

Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

A Fresh Look at Oruka Therapeutics (ORKA) Valuation After Promising Clinical Data and New Financing

Simply Wall St.

Oruka Therapeutics (ORKA) Gets a Buy from BTIG

U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare

Assessing Oruka Therapeutics (ORKA) Valuation Following Promising Data on Next-Generation Psoriasis Antibody

Simply Wall St.

How Oruka’s US$756 Million Share Issue and Annual Psoriasis Therapy Could Shape ORKA’s Investment Outlook

Simply Wall St.

Oruka Therapeutics to Present at Guggenheim Healthcare Innovation Conference

Oruka Therapeutics Inc : Guggenheim Initiates Coverage With Buy Rating; Price Target $60

THOMSON REUTERS

Oruka Therapeutics initiated with a Buy at Guggenheim

Oruka Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $40 From $45

THOMSON REUTERS

Assessing Oruka Therapeutics (ORKA) Valuation Following Pipeline Advances and Rising Investor Interest

Simply Wall St.

Oruka Therapeutics (ORKA) Has a New Rating from Barclays

Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing

Oruka Therapeutics Inc: Files for Mixed Shelf of Upto $500 Mln - SEC Filing

THOMSON REUTERS

Oruka Therapeutics files to sell 39.43M shares of common stock for holders

Oruka Therapeutics Up Nearly 30%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk

Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis

Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORKA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":30.84,"timestamp":1764968400000,"preClose":30.93,"halted":0,"volume":355181,"hourTrading":{"tag":"盘后","latestPrice":30.84,"preClose":30.84,"latestTime":"17:01 EST","volume":7242,"amount":223343.28,"timestamp":1764972097498},"delay":0,"floatShares":22408091,"shares":48409232,"eps":-1.696136,"marketStatus":"Market Closed","change":-0.09,"latestTime":"12-05 16:00:00 EST","open":31.2,"high":31.8,"low":30.22,"amount":10954855.041801,"amplitude":0.051083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.696136,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":30.93,"preHourTrading":{"tag":"盘前","latestPrice":30.93,"preClose":30.93,"latestTime":"08:00 EST","volume":7,"amount":216.899998,"timestamp":1764939600154},"postHourTrading":{"tag":"盘后","latestPrice":30.84,"preClose":30.84,"latestTime":"17:01 EST","volume":7242,"amount":223343.28,"timestamp":1764972097498},"volumeRatio":0.9805854672081822,"impliedVol":1.0002,"impliedVolPercentile":0.6701},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":22408091,"roa":"--","roe":"--","lyrEps":-3.873702,"volumeRatio":0.9805854672081822,"shares":48409232,"dividePrice":0,"high":31.8,"amplitude":0.051083,"preClose":30.93,"low":30.22,"week52Low":5.485,"pbRate":"3.09","week52High":31.8,"institutionHeld":0.9835,"latestPrice":30.84,"eps":-1.696136,"divideRate":0,"volume":355181,"delay":0,"ttmEps":-1.696136,"open":31.2,"prevYearClose":19.39,"prevWeekClose":30.1,"prevMonthClose":30.1,"prevQuarterClose":19.23,"fiveDayClose":30.1,"twentyDayClose":28.28,"sixtyDayClose":16.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ORKA","fiscalQuarterEnding":"2025/09","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.55},{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12},{"date":"2024-08-29","symbol":"ORKA","amount":1.613,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-26","defaultRemindTime":1724938200000,"name":"方舟生物医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-28","payableDate":"2024-08-26","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-28"},{"market":"US","date":"2024-08-01","symbol":"ORKA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-04-25","symbol":"ORKA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"post","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5833,"buy":0.4167,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5833,"analysts":12,"updateTime":1761541200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2025-12-05","current":-18.182504,"percent":0,"low":-13.706211,"twenty":-11.478098,"median":-5.012542,"eighty":-4.13656,"high":-2.779284,"avg":-6.337329,"sd":3.256068,"marketCap":1497297545},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-27","current":-4.136846,"twenty":-4.523383,"median":-4.154632,"eighty":-3.785238,"marketCap":435433131},{"date":"2025-07-03","current":-4.48188,"twenty":-4.48188,"median":-4.154632,"eighty":-3.808193,"marketCap":471750426},{"date":"2025-07-11","current":-5.004766,"twenty":-4.566552,"median":-4.184867,"eighty":-3.812292,"marketCap":526787975},{"date":"2025-07-18","current":-5.463625,"twenty":-4.701827,"median":-4.197316,"eighty":-3.861483,"marketCap":575086233},{"date":"2025-07-25","current":-5.061679,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"marketCap":532778457},{"date":"2025-08-01","current":-4.834028,"twenty":-4.898055,"median":-4.257786,"eighty":-3.894967,"marketCap":508816530},{"date":"2025-08-08","current":-4.862484,"twenty":-4.898591,"median":-4.281656,"eighty":-3.898524,"marketCap":511811771},{"date":"2025-08-15","current":-5.221398,"twenty":-4.905169,"median":-4.336041,"eighty":-3.910674,"marketCap":561761175},{"date":"2025-08-22","current":-5.148299,"twenty":-5.001209,"median":-4.36364,"eighty":-3.910674,"marketCap":553896518},{"date":"2025-08-29","current":-5.315383,"twenty":-5.050833,"median":-4.460538,"eighty":-3.918873,"marketCap":571872876},{"date":"2025-09-05","current":-5.210955,"twenty":-5.062675,"median":-4.474766,"eighty":-3.936742,"marketCap":560637652},{"date":"2025-09-12","current":-5.621705,"twenty":-5.07235,"median":-4.48188,"eighty":-3.943016,"marketCap":604829531},{"date":"2025-09-19","current":-5.771385,"twenty":-5.152476,"median":-4.546056,"eighty":-3.972962,"marketCap":620933352},{"date":"2025-09-26","current":-5.238803,"twenty":-5.191462,"median":-4.609934,"eighty":-3.980356,"marketCap":563633712},{"date":"2025-10-03","current":-6.676428,"twenty":-5.243928,"median":-4.669033,"eighty":-3.986032,"marketCap":718305289},{"date":"2025-10-10","current":-11.49024,"twenty":-5.309118,"median":-4.714571,"eighty":-3.994896,"marketCap":1236215032},{"date":"2025-10-17","current":-11.944453,"twenty":-5.339054,"median":-4.762887,"eighty":-3.996758,"marketCap":1285083024},{"date":"2025-10-24","current":-12.200791,"twenty":-5.382217,"median":-4.835807,"eighty":-4.005866,"marketCap":1312661989},{"date":"2025-10-31","current":-12.641513,"twenty":-5.468786,"median":-4.862484,"eighty":-4.057038,"marketCap":1360078456},{"date":"2025-11-07","current":-12.717965,"twenty":-5.593858,"median":-4.890941,"eighty":-4.0778,"marketCap":1368303762},{"date":"2025-11-14","current":-11.869655,"twenty":-5.811068,"median":-4.898591,"eighty":-4.08882,"marketCap":1277035540},{"date":"2025-11-21","current":-11.960253,"twenty":-6.69801,"median":-4.937534,"eighty":-4.127114,"marketCap":1306565171},{"date":"2025-11-28","current":-13.338408,"twenty":-7.110152,"median":-4.992317,"eighty":-4.136132,"marketCap":1457117883},{"date":"2025-12-05","current":-13.706211,"twenty":-11.478098,"median":-5.012542,"eighty":-4.13656,"marketCap":1497297545}],"updateTime":1765060896971},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1110077724","title":"Kaishan Group's Subsidiary KS ORKA Signs Joint Venture LOI with Hungarian Partner to Advance Geothermal Power Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=1110077724","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110077724?lang=en_us&edition=fundamental","pubTime":"2025-11-27 12:06","pubTimestamp":1764216401,"startTime":"0","endTime":"0","summary":"Kaishan Group Co., Ltd. (300257.SZ) announced that its wholly-owned subsidiary, KS ORKA Renewables Pte Ltd (\"KS ORKA\"), recently signed a Letter of Intent (LOI) with Hungarian company Bölény Zrt...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0196","BK0117","BK0259","300257","BK0188","ORKA","BK0070"],"gpt_icon":0},{"id":"2584994459","title":"Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584994459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584994459?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:35","pubTimestamp":1763559322,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Oruka Therapeutics, with a price target of $45.00. According to Ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2584250649","title":"A Fresh Look at Oruka Therapeutics (ORKA) Valuation After Promising Clinical Data and New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584250649","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584250649?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:20","pubTimestamp":1763364046,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) stock is catching investor attention after the company shared promising Phase 1 results for ORKA-001, suggesting the potential for annual dosing in psoriasis and longer remission. The completion of new financing also strengthens its balance sheet for upcoming trials.\nSee our latest analysis for Oruka Therapeutics.\nMomentum in Oruka Therapeutics stock has clearly accelerated as fresh trial data and new financing caught investors’ attention. The share price is up an...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/a-fresh-look-at-oruka-therapeutics-orka-valuation-after-prom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/a-fresh-look-at-oruka-therapeutics-orka-valuation-after-prom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2583210561","title":"Oruka Therapeutics (ORKA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583210561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583210561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:37","pubTimestamp":1763033864,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a price target of $63.00. The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2583855979","title":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2583855979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583855979?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:46","pubTimestamp":1763019995,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP0H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1880398471.USD","PRVA","CSCO","LU0868494617.USD","JNJ","GLXY","AKAM","AMGN","BCSF","LCID","LU2361045086.USD","VAC","HTFL","MRK","BK4534","ANAB","CCOI","BRBR","LWAY","ORKA","BMY","CELC","NXT","HHH","KMI","AMN","LU1046421795.USD","KBDC","KRRO","LPRO","LU1221951046.USD","CVX","LU1221951129.SGD","LU1974910355.USD","GFS","BK4020","PCH","CRMD","LEGN","ABBV","LU2417539215.USD","DHC","GILD","ALB","FTCI"],"gpt_icon":1},{"id":"2582840323","title":"Assessing Oruka Therapeutics (ORKA) Valuation Following Promising Data on Next-Generation Psoriasis Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2582840323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582840323?lang=en_us&edition=fundamental","pubTime":"2025-11-10 13:19","pubTimestamp":1762751943,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has been gaining attention following new data from its investigational psoriasis therapy, ORKA-001. The antibody’s long half-life and convenient dosing profile have sparked discussion among investors and clinicians alike.\nSee our latest analysis for Oruka Therapeutics.\nOruka Therapeutics has seen considerable attention in recent months, with momentum building as shares climbed 13.3% over the past month and a striking 112.6% over the last quarter. Clinical progress...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-promis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-promis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2582864207","title":"How Oruka’s US$756 Million Share Issue and Annual Psoriasis Therapy Could Shape ORKA’s Investment Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864207","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582864207?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:26","pubTimestamp":1762637189,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics recently closed a shelf registration, issuing 39,425,806 shares of common stock for US$756.19 million.\nA key development supporting this event is the company’s ORKA-001 candidate, which showed a long half-life and promising safety profile in phase 1 studies for psoriasis, potentially enabling once-yearly dosing.\nWe’ll explore how the prospect of annual administration with ORKA-001 could influence Oruka’s investment narrative moving forward.\nUncover the next big thing with...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/how-orukas-us756-million-share-issue-and-annual-psoriasis-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/how-orukas-us756-million-share-issue-and-annual-psoriasis-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2579745539","title":"Oruka Therapeutics to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579745539","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579745539?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735646,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc., a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL2KbX0t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","ORKA","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2578466456","title":"Oruka Therapeutics Inc : Guggenheim Initiates Coverage With Buy Rating; Price Target $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2578466456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578466456?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:22","pubTimestamp":1761567760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nFWN3W81SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2578178156","title":"Oruka Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2578178156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578178156?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:30","pubTimestamp":1761561011,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $60 price target citing a positive view of its two highly optimize...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ORKA","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2578614235","title":"Oruka Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $40 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2578614235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578614235?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:17","pubTimestamp":1761560253,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nAZN4PLMKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2578165306","title":"Assessing Oruka Therapeutics (ORKA) Valuation Following Pipeline Advances and Rising Investor Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2578165306","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578165306?lang=en_us&edition=fundamental","pubTime":"2025-10-27 13:13","pubTimestamp":1761542033,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) is drawing investor attention following recent news coverage focused on its progress with clinical-stage monoclonal antibody treatments for psoriasis and inflammatory conditions. Recent developments in its pipeline, particularly regarding ORKA-001, are fueling curiosity.\nSee our latest analysis for Oruka Therapeutics.\nORKA’s recent clinical progress has certainly attracted attention, and the share price has responded with a 94.5% return over the past 90 days and a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-pipeli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-pipeli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2575422331","title":"Oruka Therapeutics (ORKA) Has a New Rating from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2575422331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575422331?lang=en_us&edition=fundamental","pubTime":"2025-10-13 14:15","pubTimestamp":1760336130,"startTime":"0","endTime":"0","summary":"In a report released on October 10, from Barclays initiated coverage with a Buy rating on Oruka Therapeutics and a price target of $48.00. The comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-has-a-new-rating-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-has-a-new-rating-from-barclays-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2574746285","title":"Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574746285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574746285?lang=en_us&edition=fundamental","pubTime":"2025-10-12 09:05","pubTimestamp":1760231132,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst David Risinger reiterated a Buy rating on Oruka Therapeutics on October 8. The company’s shares closed last Friday at $24....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2572636429","title":"BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636429?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:31","pubTimestamp":1759527101,"startTime":"0","endTime":"0","summary":"BRIEF-Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC FilingOct 3  - Oruka Therapeutics Inc ORKA.O:ORUKA THERAPEUTICS INC: FILES FOR MIXED SHELF OF UPTO $500 MILLION - SEC FILINGSource text: [ID:n0001213900-25-096198]Further company coverage: ORKA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2572636433","title":"Oruka Therapeutics Inc: Files for Mixed Shelf of Upto $500 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636433?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:30","pubTimestamp":1759527013,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2572636058","title":"Oruka Therapeutics files to sell 39.43M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636058","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636058?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:25","pubTimestamp":1759526706,"startTime":"0","endTime":"0","summary":"17:21 EDT Oruka Therapeutics (ORKA) files to sell 39.43M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-files-to-sell-39-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oruka-therapeutics-files-to-sell-39-43m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2571351966","title":"Oruka Therapeutics Up Nearly 30%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2571351966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571351966?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:02","pubTimestamp":1759168920,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc.  is currently at $19.72, up $4.52 or 29.74%. --Would be highest close since Jan. 6, 2025, when it closed at $20.52. --On pace for largest percent increase since April 3, 2024, when it rose 90.06%. --Currently up two consecutive days; up 31.03% over this period. --Up 33.24% month-to-date; on pace for best month since April 2024, when it rose 98.3%. --Down 100% from its all-time closing high of $68720424.00 on Feb. 18, 2000. --Down 19.54% from 52 weeks ago , when it closed at $24.51. --Up 190.86% from its 52-week closing low of $6.78 on April 8, 2025. --Traded as high as $19.99; highest intraday level since Jan. 7, 2025, when it hit $20.88","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","ORKA","BK4139"],"gpt_icon":0},{"id":"2571593273","title":"Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2571593273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571593273?lang=en_us&edition=fundamental","pubTime":"2025-09-30 01:15","pubTimestamp":1759166127,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on September 27. David Risinger has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oruka-therapeutics-orka-002-promising-alternative-with-competitive-edge-in-hidradenitis-suppurativa-and-psoriasis-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oruka-therapeutics-orka-002-promising-alternative-with-competitive-edge-in-hidradenitis-suppurativa-and-psoriasis-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2571435934","title":"Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news","url":"https://stock-news.laohu8.com/highlight/detail?id=2571435934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571435934?lang=en_us&edition=fundamental","pubTime":"2025-09-30 01:10","pubTimestamp":1759165808,"startTime":"0","endTime":"0","summary":"Leerink expects Oruka Therapeutics (ORKA) shares to trade higher following MoonLake Immunotherapeutics’ (MLTX) disclosure of mixed Phase 3 results ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-sees-greater-opportunity-for-orukas-orka-002-after-moonlake-news-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-sees-greater-opportunity-for-orukas-orka-002-after-moonlake-news-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}